A Study of YL202 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer and Breast Cancer
Trial status:Recruiting
Trial ID:
YL202-INT-101-01
NCT ID:
EudraCT ID:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
MediLink Therapeutics (Suzhou) Co., Ltd.
Recruiting
Trial Details
This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.
Medical Condition
Trial Drug
Phase
Phase 1
Type
Interventional
Estimated Enrolment
80
Estimated Trial Date
Dec 2022 - Dec 2025
Trial Participant Requirements
Age
18+ years
Sex
Female & Male
Healthy Volunteers
No
Trial Locations
Location
Status
Location
BRCR Global
Plantation, Florida, United States, 33322
Status
Recruiting
Location
Karmanos Cancer Institute
Detroit, Michigan, United States, 48201
Status
Recruiting
Location
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Status
Recruiting
Location
Next Oncology-Dallas
Irving, Texas, United States, 75039
Status
Recruiting
Location
UT health east Texas HOPE Cancer Center
Tyler, Texas, United States, 75701
Status
Recruiting
Location
Next Oncology-Virginia
Fairfax, Virginia, United States, 22031
Status
Recruiting